CRYSTAL BROWN: Open Payments
NPI 1063431716 · FORT VALLEY, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$723 in 43 payments from 12 companies in 2025. Trend: 2023 $648 · 2024 $798 · 2025 $723
Food & beverage: $723
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 15 | $155 |
| AstraZeneca Pharmaceuticals LP | 8 | $144 |
| Sumitomo Pharma America, Inc. | 4 | $81 |
| ABBVIE INC. | 3 | $68 |
| Insulet Corporation | 2 | $54 |
| Novo Nordisk Inc | 2 | $50 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $46 |
| Lilly USA, LLC | 2 | $46 |
| GlaxoSmithKline, LLC. | 1 | $20 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
Products named: OTEZLA, GEMTESA, FARXIGA, Omnipod, VRAYLAR, CAPLYTA, MOUNJARO, BREZTRI.
Industry payments across GA — which companies pay providers there.
